Dark

Check out our Level2View

ALLK
Allakos Inc.
stock NASDAQ

Inactive

May 14, 2025

0.3291USD-0.061%(-0.0002)725,841

Pre-market

0.00USD-100.000%(-0.33)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 28, 2021

08:44AM EST HC Wainwright & Co. Maintains Buy on Allakos, Lowers Price Target to $20 Benzinga

Dec 26, 2021

09:53AM EST The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year Benzinga

Dec 23, 2021

02:32PM EST Mid-Afternoon Market Update: Dow Surges 275 Points; SciPlay Shares Slide Benzinga

12:11PM EST Mid-Day Market Update: Nasdaq Rises 100 Points; Quidel Shares Plummet Benzinga

10:20AM EST Allakos Gains 14% After Tanking On Wednesday RTTNews

08:08AM EST Goldman Sachs Maintains Neutral on Allakos, Lowers Price Target to $60 Benzinga

08:00AM EST Benzinga Pro's Top 5 Stocks To Watch For Thursday, Dec. 23, 2021 (Happy Holidays! Edition): NVAX, CROX, ADTH, KXIN, ALLK Benzinga

07:50AM EST 10 Biggest Price Target Changes For Thursday Benzinga

07:23AM EST Morgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $10 Benzinga

Dec 22, 2021

02:53PM EST Mid-Afternoon Market Update: CalAmp Drops After Q3 Results; Red Cat Holdings Shares Surge Benzinga

12:16PM EST Mid-Day Market Update: Nasdaq Rises Over 100 Points; Allakos Shares Plunge Benzinga

10:42AM EST Expert Ratings For Allakos Benzinga

10:23AM EST Mid-Morning Market Update: Markets Edge Higher; CarMax Profit Tops Estimates Benzinga

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 Benzinga

09:02AM EST Jefferies Downgrades Allakos to Hold Benzinga

08:37AM EST Cowen & Co. Downgrades Allakos to Market Perform Benzinga

07:49AM EST SVB Leerink Downgrades Allakos to Market Perform, Lowers Price Target to $17 Benzinga

07:42AM EST The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda Benzinga

07:11AM EST Allakos Shares Resume Trading; Shares Down $75 from Tuesday Close Benzinga

07:08AM EST William Blair Downgrades Allakos to Market Perform Benzinga

07:07AM EST Allakos Shares to Resume Trading at 7:10 AM ET; Co Announced Tuesday; Co Announced Enigma 2 and Kryptos Studies Did Not Achieve Statistical Significance on Patient Reported Symptomatic Co-primary Endpoints Benzinga

06:24AM EST Barclays Maintains Underweight on Allakos, Lowers Price Target to $8 Benzinga

Dec 21, 2021

07:15PM EST Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and GlobeNewswire Inc

Dec 13, 2021

10:16AM EST B of A Securities Maintains Buy on Allakos, Raises Price Target to $155 Benzinga

09:43AM EST Allakos Sponsored Study Titled 'A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis (ATLAS)' Posted To ClinicalTrials.gov; Study Is Recruiting Benzinga

Nov 30, 2021

04:43PM EST Allakos Announces Expansion Of Lirentelimab Development Into Atopic Dermatitis, Chronic Spontaneous Urticaria And Asthma Benzinga

07:00AM EST Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022 Additional indications planned in 2023 GlobeNewswire Inc

Nov 10, 2021

09:10AM EST Morgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $86 Benzinga

Nov 9, 2021

11:08AM EST Allakos Q3 EPS $(1.16) Misses $(1.12) Estimate Benzinga

Nov 8, 2021

04:05PM EST Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021. GlobeNewswire Inc

Oct 25, 2021

08:19AM EDT Allakos Highlights Presentation Of Data At American College of Gastroenterology Meeting Showing Rates Of Eosinophilic Gastritis And/Or Eosinophilic Duodenitis With Systematic Evaluation Benzinga

08:00AM EDT Study shows 45%(181/405) ofpatients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria foreosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) Presentation selected for ACG Presidential Poster Award GlobeNewswire Inc

Oct 24, 2021

03:35PM EDT Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting. GlobeNewswire Inc

Aug 26, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021 Benzinga

07:56AM EDT Morgan Stanley Initiates Coverage On Allakos with Equal-Weight Rating, Announces Price Target of $88 Benzinga

Aug 9, 2021

04:15PM EDT Allakos Q2 EPS $(1.07) Down From $(0.80) YoY Benzinga

04:01PM EDT Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the second quarter endedJune 30, 2021. GlobeNewswire Inc

Jul 15, 2021

06:35AM EDT Cowen & Co. Initiates Coverage On Allakos with Outperform Rating Benzinga

Jun 7, 2021

08:10AM EDT Allakos Completes Patient Enrollment In Phase 3 Eosinophilic Gastritis And/Or Eosinophilic Duodenitis And Phase 2/3 Eosinophilic Esophagitis Clinical Trials Of Lirentelimab Benzinga

08:00AM EDT -- Results from both clinical trials expected in the fourth quarter of 2021 -- GlobeNewswire Inc

May 24, 2021

07:03AM EDT New Allakos Data Presented At DDW 2021 Suggest That Eosinophilic Gastritis And/Or Eosinophilic Duodenitis Is Highly Underdiagnosed And May Be A Common Cause Of Moderate-to-severe Gastrointestinal Symptoms Benzinga

07:00AM EDT New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic GlobeNewswire Inc

May 18, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 Benzinga

06:20AM EDT HC Wainwright & Co. Initiates Coverage On Allakos with Buy Rating, Announces Price Target of $230 Benzinga

May 10, 2021

04:18PM EDT Allakos Q1 EPS $(1.04) Down From $(0.57) YoY Benzinga

04:01PM EDT Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter endedMarch 31, 2021 and provided a business update. GlobeNewswire Inc

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 19, 2021

04:03PM EDT Allakos Appoints Baird Radford as Chief Financial Officer Benzinga

Mar 30, 2021

08:00AM EDT Allakos Inc. (the Company or Allakos) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting. GlobeNewswire Inc

Mar 1, 2021

08:03AM EST Allakos Q4 EPS $(0.86) Down From $(0.51) YoY Benzinga

08:00AM EST Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year endedDecember 31, 2020 and provided a business update. GlobeNewswire Inc

Jan 15, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021 Benzinga

08:35AM EST B of A Securities Initiates Coverage On Allakos with Buy Rating, Announces Price Target of $145 Benzinga

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

04:05PM EST Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. GlobeNewswire Inc

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 21, 2020

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 21, 2020 Benzinga

08:05AM EST SVB Leerink Initiates Coverage On Allakos with Outperform Rating, Announces Price Target of $150 Benzinga

Nov 9, 2020

08:04AM EST Allakos Q3 EPS $(0.86) Misses $(0.82) Estimate Benzinga

08:01AM EST Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter endedSeptember 30, 2020 and provided an update of its ongoing development activities. GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

03:01PM EST Notable Earnings Watchlist For Monday, Nov. 9, 2020 Before Market Open: CARS, CGC, ALLK, MCD, BIP Benzinga

Nov 2, 2020

08:07AM EST Allakos Announces Presentation From Its Eosinophilic Gastrointestinal Diseases Program At The American College Of Gastroenterology (ACG) 2020 Annual Scientific Meeting Benzinga

08:00AM EST Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last weeks American College of Gastroenterology2020 Virtual Annual Scientific Meeting. GlobeNewswire Inc

Oct 27, 2020

04:12PM EDT Allakos Reports $250M Common Stock Offering Benzinga

04:09PM EDT Allakos Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

Oct 26, 2020

07:06AM EDT Allakos Announces Results From Phase 1 Study Of Subcutaneously Administered Lirentelimab; Co. Says Based On Results, Intends To Investigate Monthly Dosing Of The Subcutaneous Formulation Of Lirentelimab Benzinga

07:04AM EDT Allakos Announces Results From Phase 1 Study Of Subcutaneously Administered Lirentelimab RTTNews

07:00AM EDT --45% (181/405) ofsymptomatic patients biopsied with chronic functional gastrointestinal symptoms met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis -- GlobeNewswire Inc

07:00AM EDT -- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustainedeosinophil suppressionsupporting once monthly dosing-- GlobeNewswire Inc

Oct 21, 2020

05:00PM EDT Allakos Highlights Publication Of Results From Phase 2 Study Of Lirentelimab In Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis in the New England Journal of Medicine Benzinga

05:00PM EDT Allakos Announces Publication of Results from the Phase 2 Study of GlobeNewswire Inc

Aug 10, 2020

11:19AM EDT Allakos shares are trading lower after the company reported worse-than-expected Q2 EPS results. Benzinga

08:29AM EDT Allakos Q2 EPS $(0.80) Misses $(0.61) Estimate Benzinga

08:00AM EDT Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter endedJune 30, 2020 and provided an update of its ongoing development activities. GlobeNewswire Inc

Share